Par’Immune is based on 20 years of academic research and clinical work on the parasitic protein P28GST. The immunomodulatory activity of the protein has been validated in several experimental models of chronic inflammatory diseases. Par’Immune aims at developing proprietary and innovative “first-in-class” therapeutic products against immune-mediated inflammatory diseases.
